Silexion Therapeutics Corp · Stock award · Ordinary Shares

What does this filing report?

An SEC Form 4 filing for Silexion Therapeutics Corp records a stock award involving Ordinary Shares on February 9, 2025. The reported quantity was 1,587. The filing date is December 31, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

Represents ordinary shares underlying RSUs granted to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer for director services provided by the Reporting Person and Shlomo Noy. The shares subject to this award vest in full on the first anniversary of the grant date, subject to the Reporting Person's or Dr. Noy's (each, with respect to half of the shares) continued service through such date.

F2

The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.

F3

The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.

F4

There were no transactions effected in respect of the ordinary shares reported in this row, and the holdings in this row are being included for informational purposes only.

F5

The number of ordinary shares reported in this row has been adjusted downwards to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.

F6

Represents stock options granted by the Issuer to GIBF for director services provided by the Reporting Person and Shlomo Noy (each, with respect to half of the options).

F7

The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025.

F8

All of the stock options reported in this row vest (and become exercisable) on the first anniversary of the grant date (i.e., on February 9, 2026), subject to the Reporting Person's or Dr. Noy's (each, with respect to half of the options) continued service through such date.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.